BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GlaxoSmithKline 

Great West Road

Brentford  Middlesex  TW8 9BD  United Kingdom
Phone: 020-8975-2000-U-K-or-800-366-8900-U-S Fax:


SEARCH JOBS




GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.

GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.

GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.

The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.

Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.

GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.

GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.

Last Updated 11-01-01


 Key Statistics


Email:
Ownership: Public

Web Site: GlaxoSmithKline
Employees:
Symbol: GSK
 





Collaborations

Beyond Genomics, Inc. 

AVANIR Pharmaceuticals 

Pharmagene Laboratories Limited 

Aradigm Corporation  Agreement to develop AERx technology for the delivery of morphine and fentanyl for pain management.

CuraGen Corporation (Acquired by Celldex Therapeutics, Inc.)  Product Discovery and Pharmacogenomics

Paratek Pharmaceuticals, Inc. 

Agenus 

ChemoCentryx, Inc. 

Gilead Sciences, Inc. 

Gilead Sciences, Inc. (Seattle, WA) 

Gilead Sciences, Inc. (Durham, NC) 

MedImmune 

Vertex Pharmaceuticals (MA)  (VX-409 and Backup Compounds)

Ligand Pharmaceuticals Inc.  - In 1995, we entered into a research and development collaboration with SmithKline Beecham (now GlaxoSmithKline) to use our proprietary expertise to discover and characterize small-molecule, orally bioavailable drugs to control hematopoiesis (the formation and development of blood cells) for the treatment of a variety of blood cell deficiencies. Eltrombopag and a back up compound, SB-559448, resulted from this collaboration. These compounds are orally active, non-peptide, small molecule thrombopoietin (TPO) mimetics for the treatment of thrombocytopenia (low platelet counts). Eltrombopag is in Phase III clinical trials for immune thrombocytopenic purpura (ITP). GlaxoSmithKline plans to file an NDA for the ITP indication in late 2007/early 2008. A Phase III clinical trial in patients with hepatitis C is planned in 2H07. In addition, Phase I/II studies are ongoing in patients with chemotherapy-induced thrombocytopenia. The backup compound, SB-559448, is in Phase I clinical trials.

EPIX Pharmaceuticals, Inc. 





 Company News
GlaxoSmithKline (GSK) Shareholders To Vote On Novartis AG (NVS) Deal On Dec. 18 11/24/2014 6:07:32 AM
Clovis Oncology (CLVS) Rises On News Of GlaxoSmithKline (GSK) Oncology Collaboration 11/18/2014 7:59:35 AM
Medidata Solutions, Inc. Collaborates With GlaxoSmithKline (GSK) On Mobile Health Initiative To Test Novel Technology For Clinical Trial Optimization 11/17/2014 12:06:45 PM
GlaxoSmithKline (GSK) Release: Families And Flu: What You Need To Know Now 11/17/2014 11:20:43 AM
PE Firm To Bid For GlaxoSmithKline (GSK)'s $3 Billion Mature Drugs Portfolio 11/14/2014 6:15:04 AM
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Announces EU Regulatory Submission For Severe Aplastic Anemia Indication For Revolade™ (Eltrombopag) 11/12/2014 10:38:58 AM
GlaxoSmithKline (GSK) Survey Points to Rise of COPD in U.S. 11/11/2014 9:00:36 AM
GlaxoSmithKline (GSK) Release: Barriers Remain In Educating People With Diabetes Of Their Increased Hepatitis B Risk 11/6/2014 1:29:20 PM
GlaxoSmithKline (GSK) Discloses Good Efficacy In Psoriasis With GSK2856184 11/6/2014 9:25:03 AM
Tiny Group Of GlaxoSmithKline (GSK) Scientists Work To Rebuild Cancer Line-Up 11/6/2014 6:31:36 AM
12345678910...